enGene Holdings Inc. (ENGN)
- Previous Close
14.72 - Open
14.93 - Bid 14.43 x 100
- Ask 15.73 x 100
- Day's Range
14.00 - 15.50 - 52 Week Range
6.69 - 47.17 - Volume
113,376 - Avg. Volume
54,579 - Market Cap (intraday)
683.564M - Beta (5Y Monthly) -0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.40
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
www.engene.comRecent News: ENGN
Performance Overview: ENGN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENGN
Valuation Measures
Market Cap
683.56M
Enterprise Value
622.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.96
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.31
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-106.8M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
85.65M
Total Debt/Equity (mrq)
39.31%
Levered Free Cash Flow (ttm)
--
Research Analysis: ENGN
Analyst Price Targets
Fair Value
No Fair Value available for this ticker